600196 復星醫藥
按盤價 
24.890 -0.390 (-1.543%) | 2026/03 - 三個月 人民幣(K¥) | 與去年同期 比較 | 2025/12 人民幣(K¥) | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | ||
| 營業總收入 | 10,073,223 | 6.93% | 41,661,613 | 41,067,196 | 41,399,540 | 43,951,547 | |
| 減：營業總成本 | 9,532,295 | 4.40% | 40,087,325 | 39,397,512 | 41,284,077 | 41,346,264 | |
| 其中:營業成本 | 5,066,739 | 2.98% | 20,800,103 | 21,365,574 | 21,595,309 | 23,169,690 | |
| 財務費用 | 222,341 | -19.79% | 1,153,425 | 1,110,518 | 984,323 | 647,403 | |
| 資產減值損失 | 4,114 | -139.00% | (150,063) | (96,570) | (219,742) | (272,488) | |
| 公允價值變動收益 | 160,916 | -157.11% | (322,268) | (115,939) | (427,380) | (2,498,368) | |
| 投資收益 | 617,532 | -51.81% | 3,763,778 | 2,104,607 | 3,501,993 | 4,377,843 | |
| 其中：對聯營企業和合營企業的投資收益 | 352,174 | -8.71% | 1,923,979 | 1,643,839 | 2,184,849 | 1,835,146 | |
| 營業利潤 | 1,375,376 | 1.22% | 5,228,351 | 4,245,104 | 3,307,508 | 4,656,656 | |
| 利潤總額 | 1,357,544 | 0.74% | 5,111,983 | 4,169,282 | 3,264,568 | 4,574,382 | |
| 減：所得稅費用 | 277,917 | -31.54% | 864,054 | 656,841 | 369,504 | 626,917 | |
| 淨利潤 | 1,079,628 | 14.66% | 4,247,930 | 3,512,440 | 2,895,063 | 3,947,464 | |
| 減：非控股權益 | 208,802 | 18.10% | 877,368 | 742,554 | 508,798 | 216,660 | |
| 股東淨利潤 | 870,826 | 13.87% | 3,370,562 | 2,769,887 | 2,386,266 | 3,730,805 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.330 | 13.79% | 1.270 | 1.040 | 0.890 | 1.430 | |
| 每股派息 (元) * | -- | -- | 0.390 | 0.320 | 0.270 | 0.420 | |
| 每股淨資產 (元) * | 18.404 | 2.59% | 18.252 | 17.700 | 17.110 | 16.684 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 30/04/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
